Ondansetron in the treatment of cognitive decline in Alzheimer dementia

Maurice Dysken; Michael Kuskowski; Susan Love; Nathan Billig; Richard Borison; Rachelle Doody; David Drachman; Eugene DeBoff; David Dunner; Mildred Farmer; Sanford Finkel; Norman Foster; Arthur Freeman; Neill Graff-Radford; Robert Green; George Grossberg; Hugh Hendrie; William Jagust; Lawrence Jenkyn; John Morris; Sheldon Preskorn; Mary Sano; Benjamin Seltzer; Paul Tuttle

doi:10.1097/00019442-200203000-00013

Ondansetron in the treatment of cognitive decline in Alzheimer dementia

Maurice Dysken
, Michael Kuskowski
, Susan Love
, Nathan Billig
, Richard Borison
, Rachelle Doody
, David Drachman
, Eugene DeBoff
, David Dunner
, Mildred Farmer
, Sanford Finkel
, Norman Foster
, Arthur Freeman
, Neill Graff-Radford
, Robert Green
, George Grossberg
, Hugh Hendrie
, William Jagust
, Lawrence Jenkyn
, John Morris

Sheldon Preskorn, Mary Sano, Benjamin Seltzer, Paul Tuttle

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.

Original language	English (US)
Pages (from-to)	212-215
Number of pages	4
Journal	American Journal of Geriatric Psychiatry
Volume	10
Issue number	2
DOIs	https://doi.org/10.1097/00019442-200203000-00013
State	Published - 2002

Bibliographical note

Funding Information:
This work was supported by a grant from the Glaxo Research Institute. The authors thank Joseph De Veaugh-Geiss, M.D., Alan Metz, M.D., Frank Stallone, Ph.D., and Joanne Cedrone, R.N., M.A., for their contributions to this study.

Publisher link

10.1097/00019442-200203000-00013

Find It

Find It at U of M Libraries

Cite this

Dysken, M., Kuskowski, M., Love, S., Billig, N., Borison, R., Doody, R., Drachman, D., DeBoff, E., Dunner, D., Farmer, M., Finkel, S., Foster, N., Freeman, A., Graff-Radford, N., Green, R., Grossberg, G., Hendrie, H., Jagust, W., Jenkyn, L., ... Tuttle, P. (2002). Ondansetron in the treatment of cognitive decline in Alzheimer dementia. American Journal of Geriatric Psychiatry, 10(2), 212-215. https://doi.org/10.1097/00019442-200203000-00013

Dysken, M, Kuskowski, M, Love, S, Billig, N, Borison, R, Doody, R, Drachman, D, DeBoff, E, Dunner, D, Farmer, M, Finkel, S, Foster, N, Freeman, A, Graff-Radford, N, Green, R, Grossberg, G, Hendrie, H, Jagust, W, Jenkyn, L, Morris, J, Preskorn, S, Sano, M, Seltzer, B & Tuttle, P 2002, 'Ondansetron in the treatment of cognitive decline in Alzheimer dementia', American Journal of Geriatric Psychiatry, vol. 10, no. 2, pp. 212-215. https://doi.org/10.1097/00019442-200203000-00013

@article{b44f5790c1fb41fda25745812e5d404f,

title = "Ondansetron in the treatment of cognitive decline in Alzheimer dementia",

abstract = "The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.",

author = "Maurice Dysken and Michael Kuskowski and Susan Love and Nathan Billig and Richard Borison and Rachelle Doody and David Drachman and Eugene DeBoff and David Dunner and Mildred Farmer and Sanford Finkel and Norman Foster and Arthur Freeman and Neill Graff-Radford and Robert Green and George Grossberg and Hugh Hendrie and William Jagust and Lawrence Jenkyn and John Morris and Sheldon Preskorn and Mary Sano and Benjamin Seltzer and Paul Tuttle",

note = "Funding Information: This work was supported by a grant from the Glaxo Research Institute. The authors thank Joseph De Veaugh-Geiss, M.D., Alan Metz, M.D., Frank Stallone, Ph.D., and Joanne Cedrone, R.N., M.A., for their contributions to this study. ",

year = "2002",

doi = "10.1097/00019442-200203000-00013",

language = "English (US)",

volume = "10",

pages = "212--215",

journal = "American Journal of Geriatric Psychiatry",

issn = "1064-7481",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Ondansetron in the treatment of cognitive decline in Alzheimer dementia

AU - Dysken, Maurice

AU - Kuskowski, Michael

AU - Love, Susan

AU - Billig, Nathan

AU - Borison, Richard

AU - Doody, Rachelle

AU - Drachman, David

AU - DeBoff, Eugene

AU - Dunner, David

AU - Farmer, Mildred

AU - Finkel, Sanford

AU - Foster, Norman

AU - Freeman, Arthur

AU - Graff-Radford, Neill

AU - Green, Robert

AU - Grossberg, George

AU - Hendrie, Hugh

AU - Jagust, William

AU - Jenkyn, Lawrence

AU - Morris, John

AU - Preskorn, Sheldon

AU - Sano, Mary

AU - Seltzer, Benjamin

AU - Tuttle, Paul

N1 - Funding Information: This work was supported by a grant from the Glaxo Research Institute. The authors thank Joseph De Veaugh-Geiss, M.D., Alan Metz, M.D., Frank Stallone, Ph.D., and Joanne Cedrone, R.N., M.A., for their contributions to this study.

PY - 2002

Y1 - 2002

N2 - The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.

AB - The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.

UR - https://www.scopus.com/pages/publications/17444438273

UR - https://www.scopus.com/pages/publications/17444438273#tab=citedBy

U2 - 10.1097/00019442-200203000-00013

DO - 10.1097/00019442-200203000-00013

M3 - Article

C2 - 11925283

AN - SCOPUS:17444438273

SN - 1064-7481

VL - 10

SP - 212

EP - 215

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

IS - 2

ER -

Ondansetron in the treatment of cognitive decline in Alzheimer dementia

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this